Evidence map›Paper›PMID 42919964›Full record

ArticleNature medicine2026

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma.

Justin Budka, Madison Davis, Subing Cao, Jessica Ding, Jeremy Margaitis, Wangshu Zhang, Joshua Winters, Saran Vardhanabhuti, Yohei Arihara, Chad Williams and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Justin Budka *Kite, a Gilead Company, Santa Monica, CA, USA.ORCID http://orcid.org/0000-0003-0908-1508
Madison Davis *Kite, a Gilead Company, Santa Monica, CA, USA.ORCID http://orcid.org/0000-0002-1293-8974
Subing CaoKite, a Gilead Company, Santa Monica, CA, USA.
Jessica DingKite, a Gilead Company, Santa Monica, CA, USA.
Jeremy MargaitisKite, a Gilead Company, Santa Monica, CA, USA.
Wangshu ZhangKite, a Gilead Company, Santa Monica, CA, USA.
Joshua WintersKite, a Gilead Company, Santa Monica, CA, USA.
Saran VardhanabhutiKite, a Gilead Company, Santa Monica, CA, USA.
Yohei AriharaSapporo Medical University School of Medicine, Sapporo, Japan.
Chad WilliamsKite, a Gilead Company, Santa Monica, CA, USA.
Soumya PoddarKite, a Gilead Company, Santa Monica, CA, USA.
Jerome RitzDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5526-4669
Mike MattieKite, a Gilead Company, Santa Monica, CA, USA.
Priti HegdeKite, a Gilead Company, Santa Monica, CA, USA.
David M BarrettKite, a Gilead Company, Santa Monica, CA, USA.
Rhine ShenKite, a Gilead Company, Santa Monica, CA, USA.
Simone FilostoKite, a Gilead Company, Santa Monica, CA, USA.
Davide BedognettiKite, a Gilead Company, Santa Monica, CA, USA. dbedognetti@kitepharma.com.ORCID http://orcid.org/0000-0002-5857-773X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with non-Hodgkin lymphoma (NHL) treated with chimeric antigen receptor (CAR) T cell therapy, factors associated with efficacy overlap with prognostic biomarkers. Currently, there is no consensus on optimal product characteristics. We analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel (axi-cel) from 580 patients with NHL across multiple clinical trials with long-term follow-up (median, 41.9 months). A high proportion of naive-like (CCR7

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.